Data at ECTRIMS to confirm Novartis’ Gilenya long-term efficacy on reducing brain volume loss and real-world relapse rates in MS Read more
DIA to host 8th Annual Conference: The New Clinical Research Environment in India: Implications and Opportunities Read more